Novo Nordisk Rybelsus Tablets User Manual

Product information and administration guide for Rybelsus (semaglutide) tablets in 3mg, 7mg, and 14mg strengths for type 2 diabetes treatment.


Novo Nordisk Rybelsus Tablets User Manual - cover page
Brand
Novo Nordisk
Category
Other
Document type
User Manual
Language
Chinese
Pages
23
File format
PDF
File size
869 KB
Published
17 November, 2026
Updated
17 November, 2026
MD5 checksum
9DE6AB8A36163BE8305B433065DE9CAA

About this manual

Rybelsus (semaglutide) is an oral medication used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. It is available in tablet strengths of 3 mg, 7 mg, and 14 mg.

The medication is a GLP-1 receptor agonist produced using recombinant DNA technology. It can be used as a monotherapy for patients who cannot tolerate metformin or in combination with other glucose-lowering medications. This manual is written in Chinese.

What's inside

  • 藥品名稱
  • 定性及定量組成
  • 劑型
  • 治療適應症
  • 用法用量 及投與途徑
  • 禁忌症
  • 使用時的特殊警語及注意事項

Specifications

Active Ingredientsemaglutide
Available Strengths3 mg, 7 mg, 14 mg
Sodium Content23 mg per tablet
Tablet Dimensions7.5 mm x 13.5 mm

Frequently asked questions

What is the starting dose for Rybelsus?

The starting dose is 3 mg daily for one month, then increased to a maintenance dose of 7 mg daily.

Who should not use Rybelsus?

It is contraindicated for patients with a personal or family history of medullary thyroid carcinoma (MTC) or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Download PDF (869 KB)

More Novo Nordisk Manuals


View all Novo Nordisk manuals →